Subcutaneous Tocilizumab for Cystoid Macular Edema Secondary to Juvenile Idiopathic Arthritis (JIA)-associated Uveitis: A Case Report

Alfredo Adán1 Department of Ophthalmology, Hospital Clinic of Barcelona, Barcelona, SpainCorrespondence[email protected]

https://orcid.org/0000-0002-0849-8814

, PhD, MD

Aina Moll-Udina1 Department of Ophthalmology, Hospital Clinic of Barcelona, Barcelona, Spain

https://orcid.org/0000-0003-4753-2111

, MD

Julio Ramirez2 Department of Rheumatology, Hospital Clinic of Barcelona, Barcelona, Spain

, MD &

Victor Llorenç1 Department of Ophthalmology, Hospital Clinic of Barcelona, Barcelona, Spain

https://orcid.org/0000-0002-7375-1564

, PhD, MD

References

Adán A, Mesquida M, Llorenç V, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251:2627–2632. doi:10.1007/s00417-013-2436-y.
PubMed Web of Science ®Google Scholar
Tappeiner C, Mesquida M, Adán A, et al. Evidence for Tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2016;43:2183–2188. doi:10.3899/jrheum.160231.
PubMed Web of Science ®Google Scholar
Darloy J, Segaud N, Salmon JH, Eschard JP, Goëb V, Deprez X. Tocilizumab effectiveness after switching from intravenous to subcutaneous route in patients with rheumatoid arthritis: the RoSwitch study. Rheumatol Ther. 2019;6:61–75. doi:10.1007/s40744-018-0138-y.
PubMed Web of Science ®Google Scholar
De Benedetti F, Brunner HI, Ruperto N, et al. PRINTO; PRCSG. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–2395. doi:10.1056/NEJMoa1112802.
PubMed Web of Science ®Google Scholar
Mesquida M, Molins B, Llorenç V, et al. Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina. 2018;38:1361–1370. doi:10.1097/IAE.0000000000001690.
PubMed Web of Science ®Google Scholar
Quesada-Masachs E, Caballero CM. Subcutaneous tocilizumab may be less effective than intravenous tocilizumab in the treatment of juvenile idiopathic arthritis-associated uveitis. J Rheumatol. 2017;44:260–261. doi:10.3899/jrheum.160908.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Subcutaneous Tocilizumab for Cystoid Macular Edema Secondary to Juvenile Idiopathic Arthritis (JIA)-associated Uveitis: A Case Report

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Subcutaneous Tocilizumab for Cystoid Macular Edema Secondary to Juvenile Idiopathic Arthritis (JIA)-associated Uveitis: A Case Report

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date